{
    "nct_id": "NCT03585114",
    "official_title": "Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers",
    "inclusion_criteria": "* Histologically confirmed diagnosis of prostate cancer\n* Age ≥ 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)\n* Metastatic castrate resistant prostate cancer as defined by Prostate Cancer Working Group 3\n* Eligible to receive systemic treatment (abiraterone, enzalutamide, docetaxel, cabazitaxel) for their disease\n* Ability to understand and willingness to sign a written informed consent document\n* Wiling to comply with clinical trial instructions and requirements\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another active malignancy within 3 years, other than basal cell and squamous cell carcinoma of the skin\n* Presence of prostate brachytherapy implants\n* Administration of another radioisotope within five physical half-lives of trial enrollment\n* Radiation or chemotherapy within 2 weeks prior to trial enrollment\n* Serum creatinine > 3 times the upper limit of normal\n* Serum total bilirubin > 3 times the upper limit of normal\n* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) >5 times the upper limit of normal\n* Inadequate venous access",
    "miscellaneous_criteria": ""
}